Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atazanvir/ritonavir+ efavirenz · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Atazanvir/ritonavir + efavirenz | DRUG | Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks. |
Inclusion Criteria: * Provide written informed consent * HIV positive with plasma HIV RNA viral load of ≥ 1000 copies/mL and CD4 cell count of ≥ 50 cells/mm3 * Antiretroviral (ARV) naive prior to enrollment * Normal plasma triglycerides ≤ 200 mg/dL * Women of child-bearing age must use effective ba...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Atazanavir/ritonavir plus efavirenz is a combination antiretroviral regimen studied for the treatment of HIV Infections. It combines a boosted protease inhibitor with a non-nucleoside reverse transcriptase inhibitor. The regimen was evaluated as a nucleoside sparing option, meaning it was tested without nucleoside reverse transcriptase inhibitors as part of the background therapy.
Bristol-Myers Squibb Company, which trades under the ticker BMY, is the developer associated with this atazanavir/ritonavir plus efavirenz regimen. The company sponsored the clinical study of the combination in HIV Infections.
Atazanavir/ritonavir plus efavirenz has been studied in a Phase 3 clinical trial. The trial has completed, and no active trials of this regimen are currently listed. It is an investigational combination regimen rather than a standalone approved product.
The regimen was studied in trial NCT00135343, titled A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen. It was a Phase 3, controlled, randomized trial that enrolled 60 participants with HIV Infections at sites in the United States. Participants were 18 years and older, and the study did not include healthy volunteers.
The Phase 3 trial of atazanavir/ritonavir plus efavirenz, NCT00135343, enrolled 60 participants. It was a randomized and controlled study conducted in the United States in adults with HIV Infections. The trial has completed.